Status of PCSK9 Monoclonal Antibodies in Australia

Daniel J. Scherer, Adam J. Nelson, Richard O'Brien, Karam M. Kostner, David L. Hare, David M. Colquhoun, Philip J. Barter, Philip Aylward, Stephen J. Nicholls, Gerald F. Watts

Research output: Contribution to journalReview ArticleOtherpeer-review

2 Citations (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9)monoclonal antibodies (mAb)have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.

Original languageEnglish
Pages (from-to)1571-1579
Number of pages9
JournalHeart Lung and Circulation
Volume28
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • Atherosclerosis
  • Cardiovascular risk
  • Lipids
  • PCSK9 inhibitors

Cite this